Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Caffeine and progression of Parkinson disease.

Simon DK, Swearingen CJ, Hauser RA, Trugman JM, Aminoff MJ, Singer C, Truong D, Tilley BC; NET-D Investigators.

Clin Neuropharmacol. 2008 Jul-Aug;31(4):189-96. doi: 10.1097/WNF.0b013e31815a3f03.

2.

A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease.

NINDS NET-PD Investigators.

Neurology. 2006 Mar 14;66(5):664-71. Epub 2006 Feb 15.

PMID:
16481597
3.

Caffeine and Progression of Parkinson Disease: A Deleterious Interaction With Creatine.

Simon DK, Wu C, Tilley BC, Wills AM, Aminoff MJ, Bainbridge J, Hauser RA, Schneider JS, Sharma S, Singer C, Tanner CM, Truong D, Wong PS.

Clin Neuropharmacol. 2015 Sep-Oct;38(5):163-9. doi: 10.1097/WNF.0000000000000102.

PMID:
26366971
4.

Caffeine for treatment of Parkinson disease: a randomized controlled trial.

Postuma RB, Lang AE, Munhoz RP, Charland K, Pelletier A, Moscovich M, Filla L, Zanatta D, Rios Romenets S, Altman R, Chuang R, Shah B.

Neurology. 2012 Aug 14;79(7):651-8. doi: 10.1212/WNL.0b013e318263570d. Epub 2012 Aug 1. Erratum in: Neurology. 2012 Oct 16;79(16):1744.

5.

Determinants of the timing of symptomatic treatment in early Parkinson disease: The National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) Experience.

Parashos SA, Swearingen CJ, Biglan KM, Bodis-Wollner I, Liang GS, Ross GW, Tilley BC, Shulman LM; NET-PD Investigators.

Arch Neurol. 2009 Sep;66(9):1099-104. doi: 10.1001/archneurol.2009.159. Epub 2009 Jul 13.

6.

Does levodopa slow or hasten the rate of progression of Parkinson's disease?

Fahn S; Parkinson Study Group.

J Neurol. 2005 Oct;252 Suppl 4:IV37-IV42. Review.

PMID:
16222436
7.

A pilot clinical trial of creatine and minocycline in early Parkinson disease: 18-month results.

NINDS NET-PD Investigators.

Clin Neuropharmacol. 2008 May-Jun;31(3):141-50. doi: 10.1097/WNF.0b013e3181342f32.

8.

Progression of motor and nonmotor features of Parkinson's disease and their response to treatment.

Vu TC, Nutt JG, Holford NH.

Br J Clin Pharmacol. 2012 Aug;74(2):267-83. doi: 10.1111/j.1365-2125.2012.04192.x.

9.
10.

Caffeine and risk of Parkinson's disease in a large cohort of men and women.

Palacios N, Gao X, McCullough ML, Schwarzschild MA, Shah R, Gapstur S, Ascherio A.

Mov Disord. 2012 Sep 1;27(10):1276-82. doi: 10.1002/mds.25076. Epub 2012 Aug 27.

11.

The impact of depressive symptoms in early Parkinson disease.

Ravina B, Camicioli R, Como PG, Marsh L, Jankovic J, Weintraub D, Elm J.

Neurology. 2007 Jul 24;69(4):342-7. Epub 2007 Jun 20.

12.

Caffeine in Parkinson's disease: a pilot open-label, dose-escalation study.

Altman RD, Lang AE, Postuma RB.

Mov Disord. 2011 Nov;26(13):2427-31. doi: 10.1002/mds.23873. Epub 2011 Sep 27.

PMID:
21953603
13.

Functional decline in Parkinson disease.

Jankovic J, Kapadia AS.

Arch Neurol. 2001 Oct;58(10):1611-5.

PMID:
11594919
14.

Association between caffeine intake and risk of Parkinson's disease among fast and slow metabolizers.

Tan EK, Chua E, Fook-Chong SM, Teo YY, Yuen Y, Tan L, Zhao Y.

Pharmacogenet Genomics. 2007 Nov;17(11):1001-5.

PMID:
18075470
15.

Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease.

Parkinson Study Group CALM Cohort Investigators.

Arch Neurol. 2009 May;66(5):563-70. doi: 10.1001/archneur.66.1.nct90001.

PMID:
19433655
16.

Effects of caffeine on levodopa pharmacokinetics and pharmacodynamics in Parkinson disease.

Deleu D, Jacob P, Chand P, Sarre S, Colwell A.

Neurology. 2006 Sep 12;67(5):897-9.

PMID:
16966563
17.

Urate as a predictor of the rate of clinical decline in Parkinson disease.

Ascherio A, LeWitt PA, Xu K, Eberly S, Watts A, Matson WR, Marras C, Kieburtz K, Rudolph A, Bogdanov MB, Schwid SR, Tennis M, Tanner CM, Beal MF, Lang AE, Oakes D, Fahn S, Shoulson I, Schwarzschild MA; Parkinson Study Group DATATOP Investigators.

Arch Neurol. 2009 Dec;66(12):1460-8. doi: 10.1001/archneurol.2009.247. Epub .

18.

A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease.

Parkinson Study Group.

Arch Neurol. 2004 Apr;61(4):561-6.

PMID:
15096406
19.

"Disease-modification" trials in Parkinson disease: target populations, endpoints and study design.

Rascol O.

Neurology. 2009 Feb 17;72(7 Suppl):S51-8. doi: 10.1212/WNL.0b013e318199049e. Review.

PMID:
19221315
20.

Foot-tapping rate as an objective outcome measure for Parkinson disease clinical trials.

Gunzler SA, Pavel M, Koudelka C, Carlson NE, Nutt JG.

Clin Neuropharmacol. 2009 Mar-Apr;32(2):97-102. doi: 10.1097/WNF.0B013E3181684C22.

PMID:
18978495
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk